A citation-based method for searching scientific literature

Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
Times Cited: 536



Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
Times Cited: 192




List of shared articles



Times cited

Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives.
Swapnil P Borse, Abu Sufiyan Chhipa, Vipin Sharma, Devendra Pratap Singh, Manish Nivsarkar. Med Princ Pract 2021
2

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.
Jaquellyne Gurgel Penaforte-Saboia, Carlos Eduardo Barra Couri, Natasha Vasconcelos Albuquerque, Vanessa Lauanna Lima Silva, Natália Bitar da Cunha Olegario, Virgínia Oliveira Fernandes, Renan Magalhães Montenegro Junior. Diabetes Metab Syndr Obes 2021
1

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Mirna Abd El Aziz, Oscar Cahyadi, Juris J Meier, Wolfgang E Schmidt, Michael A Nauck. Diabetes Obes Metab 2020
21


Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Chiara Montereggi, Besmir Nreu, Edoardo Mannucci, Matteo Monami. Diabetes Res Clin Pract 2020
6

Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Awadhesh Kumar Singh, Kalyan Kumar Gangopadhyay, Ritu Singh. Expert Rev Clin Pharmacol 2020
3

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti, Ali A Rizvi. Metabolism 2020
3


Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
Sanbao Chai, Shuqing Yu, Zhirong Yang, Shanshan Wu, Le Gao, Haining Wang, Yuan Zhang, Siyan Zhan, Linong Ji, Feng Sun. BMJ Open Diabetes Res Care 2019
1

Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.
Mathieu Boniol, Matteo Franchi, Maria Bota, Agnès Leclercq, Joeri Guillaume, Nancy van Damme, Giovanni Corrao, Philippe Autier, Peter Boyle. Diabetes Care 2018
13

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis.
Lana C Pinto, Dimitris V Rados, Sabrina S Barkan, Cristiane B Leitão, Jorge L Gross. Sci Rep 2018
32

The safety of gliptins : updated data in 2018.
André Jacques Scheen. Expert Opin Drug Saf 2018
41

Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis.
Jetty A Overbeek, Marina Bakker, Amber A W A van der Heijden, Myrthe P P van Herk-Sukel, Ron M C Herings, Giel Nijpels. Diabetes Metab Res Rev 2018
18

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.
Michael A Nauck, Thomas Jon Jensen, Carina Rosenkilde, Salvatore Calanna, John B Buse. Diabetes Care 2018
26